Newsfeeds - Spark Newswire

1 minute read

News

Arbutus Biopharma Issued Update on AB-729 and AB-836, an siRNA and Capsid Inhibitor Currently in Development for the Treatment of Chronic Hepatitis B Infection

By Charles Gross

Today, 10:23 PM

https://docs.publicnow.com/viewDoc?hash_primary=FDC8FA6E482AC847C1071B9C6541ED81325D0867

ABUS

2 minute read

Moderna Files Motion To Dismiss COVID-19 Vaccine Related Patent Claims: WSJ

By Vandana Singh

Today, 10:23 PM

Moderna Inc (NASDAQ: MRNA) is trying to fight off rival companies’ patent infringement claims related to its COVID-19 vaccine, arguing that the companies may only pursue their claims by seeking royalties from the federal government.

ABUS

1 minute read

Moderna Says Has Moved To Dismiss Plaintiffs Claims In Section 1498 Motion Related To Sale Of COVID Vaccine Doses To US Gov’t,. Says Claims Brought By Genevant, Arbutus Are ‘Unfounded’

By Benzinga Newsdesk

Today, 10:23 PM

-Reuters https://docs.publicnow.com/viewDoc?hash_primary=CC12F7B38BCD0D142FDE825B62D5E9876A36DFC3

ABUS

1 minute read

Arbutus Biopharma: Q1 Earnings Insights

By Benzinga Insights

Today, 10:23 PM

Arbutus Biopharma (NASDAQ:ABUS) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

ABUS

30 minute read

Earnings Scheduled For May 5, 2022

By Benzinga Insights

Today, 10:23 PM

Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.

AAOI

48 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 10:23 PM

During Thursday, 849 stocks hit new 52-week lows.

AADI

1 minute read

HC Wainwright & Co. Maintains Buy on Arbutus Biopharma, Raises Price Target to $8.5

By Benzinga Newsdesk

Today, 10:23 PM

HC Wainwright & Co. analyst Ed Arce maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and raises the price target from $8 to $8.5.

ABUS

1 minute read

Chardan Capital Maintains Buy on Arbutus Biopharma, Raises Price Target to $6

By Benzinga Newsdesk

Today, 10:23 PM

Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and raises the price target from $5.5 to $6.

ABUS

9 minute read

Earnings Scheduled For March 3, 2022

By Benzinga Insights

Today, 10:23 PM

Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million.

ABUS

9 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For February 2, 2022

By Benzinga Insights

Today, 10:23 PM

ABUS